Journal article
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, PL Kellokumpu-Lehtinen, P Bono, V Kataja, C Desmedt, MJ Piccart, S Loibl, C Denkert, MJ Smyth, H Joensuu, C Sotiriou
Annals of Oncology | OXFORD UNIV PRESS | Published : 2014
Abstract
Background: We have previously shown the prognostic importance of tumor-infiltrating lymphocytes (TILs) in newly diagnosed triple-negative breast cancer (TNBC) using tumor samples from a large clinical trial cohort. In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+). Patients and methods: A prospective-retrospective study was conducted using samples from the FinHER adjuvant, phase III trial that enrolled 1010 early-stage BC patients, 778 of whom were HER2-nonamplified. Those with HER2+ disease (n = 232) were randomized to 9 weeks of trastuzumab or no trastuzumab in addition to chemotherapy. Two ..
View full abstractGrants
Awarded by Breast Cancer Research Foundation
Funding Acknowledgements
This study was funded by the European Union Framework 7 program (EU-FP7) RESPONSIFY project (No. 278659) and the Breast Cancer Research Foundation (BCRF), NY. The funding source had no role in the study design, data analysis, data collection, data interpretation or writing of the report. SL, SM, and CS are supported by the Breast Cancer Research Foundation, NY. SL is supported by the Fonds JC Heuson, Belgium, the National Health and Medical Council of Australia (NH&MRC), and Cancer Council Victoria. MJS is supported by a NH&MRC Australia Fellowship and the Susan G. Komen Breast Cancer Foundation. HJ is supported by the Academy of Finland, Cancer Society for Finland, the Sigrid Juselius Foundation, and the Research Funds of Helsinki University Central Hospital.